Unveiling the potential biochemical effects of selected heterocyclic compounds as human Type-A γ-aminobutyric acid (GABA A) Modulator: An Approach.

BACKGROUND

Investigating the bioactivities of zuranolone derivatives as Type-A γ-aminobutyric acid inhibitors which will thereby down-regulate postpartum depression is considered a crucial study.

METHOD

This study is aimed at investigating the biochemical activities of 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3‑hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile derivatives against type-A γ-aminobutyric acid (GABA A) which will thereby enhance the activity of γ-aminobutyric acid (GABA) in human central nervous system.

RESULTS

In this work, series of computational tools such as Spartan 14, molecular operating environment software, Gromacs and Admetsar1 were explored and the studied compounds were subjected to this software which resulted to series of results. Vacuum was observed to have highest influence on highest occupied molecular orbital (E) of compound 1 and water as well as ethanol reduces its ability to donate electron to the nearby molecules. Also, the effect of water and ethanol were investigated on the studied compound via lowest unoccupied molecular orbital (E) and energy gap and the results were reported appropriately. The molecular docking investigation was carried out on the studied compounds and Type-A γ-aminobutyric acid (pdb id: 4cof) and the compounds 3 with calculated binding affinity value of -7.32433319kcal/mol as well as pi-H as the non-bonding interaction were observed which therefore confirm the potential ability of compound to inhibit the target than other studied compound. Also, compound 1 and reference compound were subjected to molecular dynamic simulation study and the actual binding energy for the selected compounds were obtained and reported.

CONCLUSION

Our findings from this work may open door for the design of several 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-(benzyloxy)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile derivatives as potential Type-A γ-aminobutyric acid inhibitors.